Clinical Report: Osimertinib as a Therapeutic Approach for Unresectable Mucoepidermoid Carcinoma
Overview
This case study presents the use of osimertinib in a 72-year-old man with unresectable mucoepidermoid carcinoma (MEC), resulting in a 33% reduction in tumor size and 13 months of disease control.
Background
Mucoepidermoid carcinoma (MEC) is the most common malignant neoplasm of the salivary glands, yet treatment options for unresectable cases are limited. Conventional chemotherapy has shown low response rates, highlighting the need for alternative therapeutic strategies. The identification of genetic alterations, particularly the CRTC1–MAML2 fusion, has opened avenues for targeted therapies such as EGFR inhibitors.
Data Highlights
No numerical data or trial data presented in the article.
Key Findings
Osimertinib was administered at 80 mg once daily to a patient with unresectable MEC.
The patient achieved a 33% reduction in tumor size, meeting RECIST 1.1 criteria for partial response.
Treatment resulted in approximately seven and a half months of disease control with grade 1 toxicity.
This case represents the first reported partial response of oral MEC to a third-generation EGFR-TKI.
Comprehensive genomic profiling revealed no high-tier actionable alterations, emphasizing the need for further research in this area.
Clinical Implications
This case highlights the use of osimertinib in a patient with unresectable MEC.
Conclusion
This case highlights the use of osimertinib as a therapeutic approach for unresectable mucoepidermoid carcinoma.
